A J Pantuck

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma
    Ken-ryu Han
    Department of Urology, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    Urology 61:314-9. 2003
  2. ncbi A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases
    Chong Xie
    Department of Urology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095 1738, USA
    J Transl Med 9:43. 2011
  3. ncbi A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer
    Mitchell Gross
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    BMC Cancer 7:142. 2007
  4. ncbi Editorial comment on: Collecting duct renal cell carcinoma: a matched analysis of 41 cases
    Allan J Pantuck
    David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Eur Urol 52:1145-6. 2007
  5. ncbi Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1738, USA
    Clin Cancer Res 12:4018-26. 2006
  6. ncbi A novel resectoscope for transurethral resection of bladder tumors and the prostate
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, 10833 Le Conte Ave, Room B7 298A CHS, Los Angeles, California 90025 1738, USA
    J Urol 178:2331-6; discussion 2336. 2007
  7. ncbi Gene and immune therapy for renal cell carcinoma
    A J Pantuck
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, California, USA
    Int J Urol 8:S1-4. 2001
  8. ncbi Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?
    Allan J Pantuck
    Departments of Urology and Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, USA
    Clin Cancer Res 13:693s-696s. 2007
  9. ncbi Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1738, USA
    Semin Oncol 33:607-13. 2006
  10. ncbi Improved prognostication of renal cell carcinoma using an integrated staging system
    A Zisman
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, CA 90095-1738, USA
    J Clin Oncol 19:1649-57. 2001

Research Grants

  1. Genetic and molecular characterization of kidney cancer
    Allan Pantuck; Fiscal Year: 2005

Detail Information

Publications96

  1. ncbi Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma
    Ken-ryu Han
    Department of Urology, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    Urology 61:314-9. 2003
    ..Survival in patients with disease limited to the lung was similar to that of patients whose disease was limited to bone...
  2. ncbi A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases
    Chong Xie
    Department of Urology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095 1738, USA
    J Transl Med 9:43. 2011
    ..One major obstacle is the lack of a sensitive and multiplex approach for quantifying autoAb against a large panel of clinically relevant tumor-associated antigens (TAA)...
  3. ncbi A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer
    Mitchell Gross
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    BMC Cancer 7:142. 2007
    ..Erlotinib is a specific inhibitor of the tyrosine-kinase activity of EGFR. The goal of this study is to determine the anti-cancer activity docetaxel combined with erlotinib for the treatment of elderly subjects with AIPC...
  4. ncbi Editorial comment on: Collecting duct renal cell carcinoma: a matched analysis of 41 cases
    Allan J Pantuck
    David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Eur Urol 52:1145-6. 2007
  5. ncbi Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1738, USA
    Clin Cancer Res 12:4018-26. 2006
    ..We sought to determine the effects of pomegranate juice (a major source of antioxidants) consumption on prostate-specific antigen (PSA) progression in men with a rising PSA following primary therapy...
  6. ncbi A novel resectoscope for transurethral resection of bladder tumors and the prostate
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, 10833 Le Conte Ave, Room B7 298A CHS, Los Angeles, California 90025 1738, USA
    J Urol 178:2331-6; discussion 2336. 2007
    ..We performed a multicenter pilot and feasibility study of a novel working element for resectoscopes designed to improve the efficacy and safety of transurethral endoscopic surgery...
  7. ncbi Gene and immune therapy for renal cell carcinoma
    A J Pantuck
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, California, USA
    Int J Urol 8:S1-4. 2001
    ..Current immunotherapy and gene therapy strategies, including methods of cytokine delivery and tumor-cell-based vaccines, are presented...
  8. ncbi Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?
    Allan J Pantuck
    Departments of Urology and Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, USA
    Clin Cancer Res 13:693s-696s. 2007
    ..Although evidence-based medical practice suggests a role for nephrectomy before the use of targeted agents, the arguments for and against this practice will be weighed...
  9. ncbi Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1738, USA
    Semin Oncol 33:607-13. 2006
    ....
  10. ncbi Improved prognostication of renal cell carcinoma using an integrated staging system
    A Zisman
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, CA 90095-1738, USA
    J Clin Oncol 19:1649-57. 2001
    ..Our data suggests that UISS is an important prognostic tool for counseling patients with various stages of kidney cancer. Further prospective large-scale validation with external data is awaited...
  11. ncbi The changing natural history of renal cell carcinoma
    A J Pantuck
    Department of Urology, University of California School of Medicine, Los Angeles, California, USA
    J Urol 166:1611-23. 2001
    ..CONCLUSIONS: Currently patients with localized and metastatic renal cell carcinoma have had improvements in outlook and the therapeutic options available have expanded...
  12. ncbi Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome
    A Zisman
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, California, USA
    J Urol 166:54-8. 2001
    ..between stages T1 and T2 tumors is too high. Lowering the cutoff to 4.5 cm. resulted in better discriminatory power of the TNM classification in our dataset. This observation should be further validated by external data...
  13. ncbi Prognostic factors and molecular markers for renal cell carcinoma
    M H Bui
    University of California School of Medicine, Department of Urology, 10833 Le Conte Avenue, Room 66-118 CHS, Los Angeles, CA 90095-1738, USA
    Expert Rev Anticancer Ther 1:565-75. 2001
    ..This review examines the clinical and molecular prognostic tools currently available or under investigation for kidney cancer...
  14. ncbi Dendritic cell-based immunotherapy of renal cell carcinoma
    B J Gitlitz
    Medical Oncology, UCLA School of Medicine, 2345D PVUB, Box 7086, Los Angeles, CA 90095 7086, USA
    Curr Urol Rep 2:46-52. 2001
    ..In vitro strategies to expand and load dendritic cells with antigens have now led to human vaccine trials in renal cell carcinoma and other malignancies...
  15. ncbi Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology
    A Belldegrun
    Department of Urology, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Hum Gene Ther 12:883-92. 2001
    ..This phase I trial demonstrated the safety of intraprostatic Leuvectin injection, with transient PSA-based responses seen after therapy...
  16. ncbi Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo
    Maryam R Sartippour
    Center for Human Nutrition, Los Angeles, CA 90095 1742, USA
    Int J Oncol 32:475-80. 2008
    ..Further studies in humans are needed to confirm that angiogenesis can be inhibited by an ellagitannin-rich pomegranate extract administered orally as a dietary supplement...
  17. ncbi Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials
    Bradley C Leibovich
    University of California-Los Angeles Kidney Cancer Program, Department of Urology, University of California-Los Angeles School of Medicine, Los Angeles, California 90095-1738, USA
    Cancer 98:2566-75. 2003
    ..The authors present a scoring algorithm based on these features that can be used to predict survival in patients who present with metastatic RCC and to stratify such patients for prospective clinical trials...
  18. ncbi Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma
    David B Seligson
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, California 90095, USA
    Clin Cancer Res 10:2659-69. 2004
    ....
  19. ncbi Prognostic factors for renal cell carcinoma with tumor thrombus extension
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1738, USA
    J Urol 178:1189-95; discussion 1195. 2007
    ..We identified prognostic factors for renal cell carcinoma with tumor thrombus extension and assessed whether the current T3 classification could be improved...
  20. ncbi Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection
    Allan J Pantuck
    Department of Urology, University of California School of Medicine, Los Angeles, California, USA
    J Urol 169:2076-83. 2003
    ..When lymph nodes are present, they should be resected when technically feasible...
  21. ncbi Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants
    Allan J Pantuck
    Department of Urology, School of Medicine, University of California-Los Angeles, Los Angeles, CA 90095, USA
    Hum Gene Ther 13:777-89. 2002
    ..Both in vitro and in vivo studies suggest improved killing with the sr39tk variant. Thus, the results suggest that the use of sr39tk in future trials of prostate cancer tk suicide gene therapy may be beneficial...
  22. ncbi Biology of renal cell carcinoma: changing concepts in classification and staging
    A J Pantuck
    Department of Urology, University of California School of Medicine, Los Angeles 90095-1738, USA
    Semin Urol Oncol 19:72-9. 2001
    ..In this review, the results of international consensus efforts to achieve uniform classification systems for RCC are outlined and some future directions are considered...
  23. ncbi Laparoscopic radical nephrectomy
    A Zisman
    Department of Urology, University of California School of Medicine, Los Angeles 90095-1738, USA
    Semin Urol Oncol 19:114-22. 2001
    ....
  24. ncbi New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions
    A J Pantuck
    UCLA School of Medicine, University of California at Los Angeles, Los Angeles, California 90095-1738, USA
    Urology 57:95-9. 2001
    ..Current results of clinical immune/gene therapy protocols will be reviewed with consideration towards the concept of cancer prevention...
  25. ncbi Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma
    John S Lam
    Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California 90095-1738, USA
    Cancer 103:2517-25. 2005
    ..In addition, Ki-67 expression served as a valuable surrogate marker for the presence of histologic tumor necrosis...
  26. ncbi Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    Cancer 109:2257-67. 2007
    ..The goal of the study was to evaluate the potential and limitations of targeting the mTOR pathway in renal cell carcinoma (RCC)...
  27. ncbi Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    BJU Int 99:821-4. 2007
    ....
  28. ncbi Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine at University of California, Los Angeles 90095, USA
    J Immunother (1997) 27:240-53. 2004
    ..These results suggest that VV/MUC-1/IL-2 gene therapy with a maximum tolerated dose of 5 x 10(7) pfu is safe and well tolerated...
  29. ncbi Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy
    Matthew H T Bui
    Department of Urology, University of California, Los Angeles, California 90095 1738, USA
    Clin Cancer Res 9:802-11. 2003
    ..To date, there are no molecular markers which can reliably predict RCC outcome. We investigated whether a novel kidney cancer marker, carbonic anhydrase IX (CAIX), is associated with progression and survival...
  30. ncbi Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis
    Satomi Koyama
    Division of Pediatric Endocrinology, Mattel Children s Hospital, David Geffen School of Medicine, University of California, Los Angeles, USA
    Growth Horm IGF Res 20:55-62. 2010
    ..These studies revealed novel interactions between the IGF system and pomegranate-induced apoptosis...
  31. ncbi CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis
    Michela de Martino
    Department of Urology, University of California Los Angeles, Los Angeles, California 90095 1738, USA
    J Urol 182:728-34. 2009
    ..The CA9 gene exons and flanking regions were amplified by polymerase chain reaction and sequenced. The monoclonal antibody M75 was used to evaluate CAIX protein expression in the primary tumor by immunohistochemistry...
  32. ncbi Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance
    Brian Shuch
    Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1738, USA
    Cancer 113:1324-31. 2008
    ..The objective of the current study was to investigate the outcomes of cytoreductive nephrectomy (CN) for patients who have an impaired performance status (ECOG PS 2/3)...
  33. ncbi Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer
    A Belldegrun
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, California, USA
    J Urol 166:1316-21. 2001
    ..CONCLUSIONS: Currently patients with advanced prostate carcinoma have expanded therapeutic options available in the form of molecular based phases II and III clinical trials...
  34. ncbi Prostate cryoablation using direct transperineal placement of ultrathin probes through a 17-gauge brachytherapy template-technique and preliminary results
    A Zisman
    Division of Urologic Oncology, Department of Urology, University of California, Los Angeles, School of Medicine, Los Angeles, California, USA
    Urology 58:988-93. 2001
    ..The preliminary results do not show an increased rate of complications compared with other published series. The clinical outcome data are preliminary. Longer follow-up data are required to draw conclusions concerning efficacy...
  35. ncbi Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis
    A Zisman
    Department of Urology, UCLA School of Medicine, University of California at Los-Angeles, 90095, USA
    J Immunother 24:459-71. 2001
    ....
  36. ncbi Molecular-based therapies for renal cell carcinoma
    A Zisman
    University of California, School of Medicine, Department of Urology, Los Angeles 90095-1738, USA
    Curr Urol Rep 2:55-61. 2001
    ..This paper reviews available gene therapies and other related therapeutic approaches for RCC and lists some of the current clinical trials focused on molecular-based therapies...
  37. ncbi Immunotherapy of prostate cancer
    S J Freedland
    University of California, Los Angeles School of Medicine, Department of Urology, 10833 Le Conte Avenue, Room 66-118 CHS, Los Angeles, CA 90095-1738, USA
    Curr Urol Rep 2:242-7. 2001
    ..This review summarizes the latest findings from each of these approaches and gives results from the few completed human clinical trials...
  38. ncbi Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma
    John T Leppert
    Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    BJU Int 96:281-5. 2005
    ....
  39. ncbi Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland
    Navindra P Seeram
    Center for Human Nutrition, Greater Los Angeles VA Medical Center, Los Angeles, California, USA
    J Agric Food Chem 55:7732-7. 2007
    ..This warrants future human tissue bioavailability studies and further clinical studies in men with CaP...
  40. ncbi Tumor biology and prognostic factors in renal cell carcinoma
    David S Finley
    Institute of Urologic Oncology, UCLA David Geffen School of Medicine, Los Angeles, California 90095 1738, USA
    Oncologist 16:4-13. 2011
    ..The discovery of prognostic factors and development of comprehensive nomograms to stratify patient risk and predictive biomarkers to facilitate individualized treatment selection and predict patient response to therapy also are reviewed...
  41. ncbi The role of molecular markers in the staging of renal cell carcinoma
    John T Leppert
    Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1738, USA
    BJU Int 99:1208-11. 2007
  42. ncbi Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy
    Karen L Reckamp
    Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA
    J Immunother 30:417-24. 2007
    ..The CXCR3/CXCR3 ligand biologic axis and angiogenic ratio may be important biomarkers in clear cell RCC patients who are undergoing high dose IL-2 therapy...
  43. ncbi Metastatic melanoma to the kidney presenting with renal vein tumor thrombus
    Tobias Klatte
    Department of Urology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1738, USA
    Urology 69:982.e7-9. 2007
    ..The patient later had tumor recurrence at multiple sites. He did not respond to systemic treatment and died 5 months later...
  44. ncbi Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience
    Tobias Klatte
    Department of Urology, University of California, Los Angeles, Los Angeles, California 90095 1738, USA, and Centre Hospitalier Universitaire Pontchaillou, Rennes, France
    J Urol 178:35-40; discussion 40. 2007
    ..We examined the current pT2 tumor classification of renal cell carcinoma and determined whether a tumor size cutoff exists that would improve prognostic accuracy...
  45. ncbi Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience
    Brian Shuch
    Department of Urology, University of California Los Angeles, Los Angeles, California 90095 1738, USA
    J Urol 181:492-8; discussion 498-9. 2009
    ..We reviewed our experience with this complication to determine frequency, mortality, common factors and management strategies...
  46. ncbi Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies
    Arie S Belldegrun
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1738, USA
    Cancer 113:2457-63. 2008
    ..The management of renal cell carcinoma (RCC) is evolving toward less extirpative surgery and the use of targeted therapy. The authors set out to provide a benchmark against which emerging therapies should be measured...
  47. ncbi Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience
    Jean-Jacques Patard
    Department of Urology, University of California Los Angeles, Los Angeles, California 90095-1738, USA
    J Urol 171:2181-5, quiz 2435. 2004
    ..This large multicenter study suggests that it is safe to expand the indications of partial nephrectomy to include patients with T1N0M0 tumors up to 7 cm. However, careful patient selection remains necessary...
  48. ncbi Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies
    Ganesh S Palapattu
    Department of Urology, David Geffen School of Medicine at UCLA, University of California-Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095-1738, USA
    J Urol 170:768-72; discussion 772. 2003
    ..CONCLUSIONS: Our findings suggest that collecting system invasion in RCC cases is associated with specific clinical findings as well as poor prognostic variables and it has a profound impact on prognosis in low stage tumors...
  49. ncbi Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system
    Stephen J Freedland
    Department of Urology, UCLA, Los Angeles, California 90095-1738, USA
    Prostate 55:299-307. 2003
    ..Clonal tumor lines may allow more accurate examination of molecular pathways involved in tumor progression and resistance to treatment...
  50. ncbi A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma
    Barbara J Gitlitz
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at University of California, Los Angeles, 10945 Le Conte Avenue, Suite 2333, Los Angeles, CA 90095, USA
    J Immunother 26:412-9. 2003
    ..Further clinical studies are needed to identify the most potent treatment regimen that can consistently mediate an antitumor immune response in vivo...
  51. ncbi Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy
    Amnon Zisman
    Kimmel Cancer Center, Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, USA
    J Urol 169:909-16. 2003
    ..The combination of surgery and immunotherapy has a role in thrombus cases. Our data provide the rationale for a prospective study of adjuvant immunotherapy after surgery in N0M0 cases with extensive tumor thrombus...
  52. ncbi Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population
    Ken-ryu Han
    Department of Urology, School of Medicine, University of California Los Angeles, 90095-1738, USA
    J Urol 170:2221-4. 2003
    ..This algorithm may be useful for patient counseling, surveillance and identification of high risk patients for enrollment in clinical trials...
  53. ncbi Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials
    John S Lam
    University of California Los Angeles Kidney Cancer Program, Division of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Le Conte Avenue, Los Angeles, CA, USA
    Clin Cancer Res 13:703s-708s. 2007
    ..This article reviews the protein expression profiles in RCC and their association with pathobiology, prognosis, and response to treatment as well as their role in serving as potential molecular targets for therapy of RCC...
  54. ncbi Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy
    Allan J Pantuck
    Department of Urology, University of California School of Medicine, Los Angeles, California 90095-1738, USA
    Cancer 97:2995-3002. 2003
    ..However, in multivariate analysis, including both clinical and pathologic variables, lymph node status was found to have less of an impact on survival than primary tumor stage and grade and patient performance status...
  55. ncbi p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma
    Oleg Shvarts
    Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California 90095-1738, USA
    J Urol 173:725-8. 2005
    ..7% and 14.4%, respectively (RR = 3.28, p = 0.018). CONCLUSIONS: p53 is a significant molecular predictor of tumor recurrence, as identified in patients undergoing treatment for localized RCC...
  56. ncbi Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker
    Gang Zeng
    Department of Urology and Jonsson Comprehensive Cancer Center, 66 118 Center for Health Sciences, David Geffen School of Medicine at UCLA, Box 951738, Los Angeles, CA 90095, USA
    Int J Cancer 114:268-73. 2005
    ..This simple and straightforward approach may allow the investigation of the clinical significance of spontaneous Ab responses against multiple TAA and their correlation with the clinical course of malignant diseases in the future...
  57. ncbi Mathematical model to predict individual survival for patients with renal cell carcinoma
    Amnon Zisman
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, CA 90095-1738, USA
    J Clin Oncol 20:1368-74. 2002
    ..On validation with external data, this type of representation can be used as a tool for the determination of personalized prognosis and may be useful for patient education and counseling...
  58. ncbi Combined cytoreductive laser therapy and immunotherapy for palliation of metastatic renal cell carcinoma to the head and neck
    M B Paiva
    Division of Head and Neck Surgery, Department of Surgery, David Geffen School of Medicine UCLA, 10833 Le Conte Avenue, CHS62 132, P O Box 162418, Los Angeles, CA 90095 1624, USA
    Lasers Med Sci 22:60-3. 2007
    ....
  59. ncbi CL1-SR39: A noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography
    Allan J Pantuck
    Department of Urology, Pharmacology and Crump Institute for Molecular Imaging, University of California School of Medicine, Los Angeles, California, USA
    J Urol 168:1193-8. 2002
    ....
  60. ncbi The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1738, USA
    J Urol 179:61-6. 2008
    ..To evaluate its role in the biology of clear cell renal cell carcinoma we performed a tissue microarray based study...
  61. ncbi Collecting duct renal cell carcinoma: clinical study of a rare tumor
    Debby Chao
    Department of Urology, Division of Urologic Oncology, University of California School of Medicine-Los Angeles, Los Angeles, CA, USA
    J Urol 167:71-4. 2002
    ..Previously recommended chemotherapy and/or immunotherapy appears to have a limited role in treatment of this disease, and early detection may be the best method for prolonging patient survival...
  62. ncbi Prognostic factors and selection for clinical studies of patients with kidney cancer
    John S Lam
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, United States
    Crit Rev Oncol Hematol 65:235-62. 2008
    ..This review will examine the current staging modalities and prognostic factors associated with RCC as well as the selection of patients most likely to benefit from clinical trials...
  63. ncbi Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable?
    Brian Shuch
    Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1738, USA
    J Urol 182:2164-71. 2009
    ..Patients with sarcomatoid features are known to have poor outcomes. We reviewed the role of surgery in this population to see if these patients could be identified preoperatively...
  64. ncbi Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Clin Cancer Res 13:7388-93. 2007
    ..Here, we evaluated the significance of HIF-1 alpha in renal cell carcinoma (RCC)...
  65. ncbi Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma
    Amnon Zisman
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, CA 90095-1738, USA
    J Clin Oncol 20:4559-66. 2002
    ..Subclassifying RCC into well-defined risk groups should allow better patient counseling and identification of both NM-HR subgroups that need adjuvant treatment and nonresponders who need alternative therapies...
  66. ncbi Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1738, USA
    Cancer 115:1448-58. 2009
    ..The objective of this study was to evaluate the role of carbonic anhydrase IX (CAIX) in urothelial carcinoma of the bladder...
  67. ncbi Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype
    Amnon Zisman
    Department of Biostatistics, University of California-Los Angeles School of Medicine, Los Angeles, CA, USA
    J Urol 168:950-5. 2002
    ..05). CONCLUSIONS: Unclassified renal cell carcinoma is associated with distinct and highly aggressive biological behavior, and poor clinical outcome. Whenever feasible, immunotherapy with nephrectomy is warranted...
  68. ncbi Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm
    Brian Shuch
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, CA 90095, USA
    BJU Int 102:692-6. 2008
    ....
  69. ncbi Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, 66 118 CHS, Box 951738, Los Angeles, CA 90095 1738, USA
    Cancer Epidemiol Biomarkers Prev 18:894-900. 2009
    ..To identify the molecular signature of localized (N0M0) clear cell renal cell carcinoma (RCC) and assess its ability to predict outcome...
  70. ncbi Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90025 1738, USA
    J Urol 179:1719-26. 2008
    ..We characterized the clinicopathological features and the prognosis of small solid renal tumors defined as tumors 4 cm or smaller...
  71. ncbi LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen
    Amnon Zisman
    Division of Urologic Oncology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Cancer Res 63:4952-9. 2003
    ..Altogether, LABAZ1 provides a relevant and flexible model to study the biology of cRCC, the role of CA IX in RCC tumorigenesis, progression, and metastasis, and a platform for testing new targeted therapeutic strategies...
  72. ncbi Current staging of renal cell carcinoma
    Bradley C Leibovich
    Department of Urology, Division of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Avenue, Suite 66-118, Los Angeles, CA 90095, USA
    Urol Clin North Am 30:481-97, viii. 2003
    ..This article focuses on the history and rationale of the current staging systems for RCC as well as the potential for improvements by the addition of other clinical, pathologic, and molecular prognostic markers...
  73. ncbi Changing concepts in the surgical management of renal cell carcinoma
    John S Lam
    Department of Urology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, 66-118 CHS, Box 951738, Los Angeles, CA 90095-1738, USA
    Eur Urol 45:692-705. 2004
    ..Here, we review current concepts and outcomes on the surgical management of RCC to help elucidate some of these changes, from the evolution of open to laparoscopic to percutaneous, from radical to partial to ablative approaches...
  74. ncbi G250: a carbonic anhydrase IX monoclonal antibody
    John S Lam
    Department of Medicine, David Geffen School of Medicine at UCLA, 2333 Peter Ueberroth Building, 10945 Le Conte Avenue, Los Angeles, CA 90095, USA
    Curr Oncol Rep 7:109-15. 2005
    ..These studies formed the basis of numerous clinical trials aimed at mAb-guided therapy in patients with metastatic RCC...
  75. ncbi Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, California 90095, USA
    Clin Cancer Res 9:4641-52. 2003
    ....
  76. ncbi Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine at UCLA, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90025, USA
    BJU Int 100:21-5. 2007
    ..To present a multicentre experience and the largest cohort to date of nonmetastatic (N0M0) synchronous bilateral renal cell carcinoma (RCC), as because it is rare the single-institutional experience is limited...
  77. ncbi Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience
    John S Lam
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, California 90095 1738, USA
    Eur Urol 52:155-62. 2007
    ..To evaluate the prognostic role of tumour size in pathological stage T3a renal cell carcinoma (RCC) with fat invasion only and to assess whether this subgroup maintains its relevance over the other pathological stages...
  78. ncbi Basic biology and clinical behavior of renal cell carcinoma
    Ken-ryu Han
    Department of Urology, University of California School of Medicine, 10833 Le Conte Avenue, Room 66-118 CHS, Los Angeles, CA 90095-1738, USA
    Cancer Treat Res 116:69-89. 2003
  79. ncbi Significance of gene expression analysis of renal cell carcinoma
    John T Leppert
    Department of Urology, David Geffen School of Medicine, UCLA, 66-118 Center for Health Sciences, Box 951738, Los Angeles, CA 90095-1738, USA
    Expert Rev Anticancer Ther 6:293-9. 2006
    ..This article reviews the significance of gene expression analysis in the understanding of tumor biology and RCC treatment...
  80. ncbi Cystic renal cell carcinoma: biology and clinical behavior
    Ken-ryu Han
    UCLA Department of Urology, Los Angeles, CA, USA
    Urol Oncol 22:410-4. 2004
    ..These findings suggest that cRCC patients may benefit from nephron sparing surgery...
  81. ncbi Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma
    Jeffrey La Rochelle
    Department of Urology, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California 90025, USA
    Cancer 116:4696-702. 2010
    ....
  82. ncbi A randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2/interferon
    Ken-ryu Han
    Curr Urol Rep 3:11-2. 2002
  83. ncbi Gene signatures of progression and metastasis in renal cell cancer
    Jon Jones
    Beth Israel Deaconess Medical Center Genomics Center and Dana-Farber/Harvard Cancer Center Proteomics Core, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:5730-9. 2005
    ..Transcriptional profiling allows a better appreciation of the molecular and clinical heterogeneity in RCC...
  84. ncbi Phase-II Study of pomegranate juice for men with prostate cancer and increasing PSA
    Allan J Pantuck
    Curr Urol Rep 7:7. 2006
  85. ncbi PC-SPES: herbal formulation for prostate cancer
    Leonard S Marks
    Urological Sciences Research Foundation, Culver City, California 90232, USA
    Urology 60:369-75; discussion 376-7. 2002
    ..PC-SPES is of great interest in men with androgen-independent CaP, an area in which future research should be primarily directed...
  86. ncbi Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma
    Allan J Pantuck
    J Clin Oncol 26:3105-7; author reply 3107-9. 2008
  87. ncbi Unclassified renal cell carcinoma: an analysis of 85 cases
    Pierre I Karakiewicz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    BJU Int 100:802-8. 2007
    ..To compare cancer-specific mortality in patients with unclassified renal cell carcinoma (URCC) vs clear cell RCC (CRCC) after nephrectomy, as URCC is a rare but very aggressive histological subtype...
  88. ncbi The prevalence of malignancy in satellite renal lesions and its surgical implication during nephron sparing surgery
    Orit Raz
    Department of Urology, Assaf Harofeh Medical Center, Zerifin, Israel
    J Urol 178:1892-5; discussion 1895. 2007
    ..We examined the prevalence of malignancy in a synchronous ipsilateral renal lesion identified during partial nephrectomy and evaluated its clinical significance...
  89. ncbi Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma
    Georg C Hutterer
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    Cancer 110:2428-33. 2007
    ..The disease-specific survival of patients with MRCC was compared according to the type of surgery, NSS (N=45) versus radical nephrectomy (RN) (N=732), in unmatched and matched analyses...
  90. ncbi Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer
    Stephen J Freedland
    Department of Urology, UCLA School of Medicine, Los Angeles, CA 90095-1738, USA
    Prostate 55:71-80. 2003
    ....
  91. ncbi Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer
    Jon Jones
    Beth Israel Deaconess Medical Center Genomics Center and Dana Farber Harvard Cancer Center Cancer Proteomics Core, Boston, Massachusetts, USA
    J Urol 179:730-6. 2008
    ....
  92. ncbi Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system
    John S Lam
    Division of Urologic Oncology, The Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California 90095, USA
    J Urol 174:466-72; discussion 472; quiz 801. 2005
    ..Patients with nodal disease also require stringent followup. Patients undergoing partial nephrectomy for localized disease can be followed according to the same UISS risk group based protocol...
  93. ncbi Long-term outcomes of the surgical management of renal cell carcinoma
    John S Lam
    Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1738, USA
    World J Urol 24:255-66. 2006
    ....
  94. ncbi Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication
    Jean Jacques Patard
    Department of Urology, Rennes University Hospital, Rennes, France
    Eur Urol 52:148-54. 2007
    ..To analyse through a large multicentre series, morbidity of nephron-sparing surgery (NSS) in relation to tumour size and surgical indication...
  95. ncbi Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma
    Ken-ryu Han
    Department of Urology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095, USA
    Urology 63:841-6; discussion 846-7. 2004
    ..However, the perioperative and postoperative complication rates were similar to those of low-risk patients. Not surprisingly, high-risk patients had greater rates of transfusions and complications...
  96. ncbi Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma
    Jean Jacques Patard
    CNRS UMR6061 Genetics and development, IFR 140, University of Rennes 1, Rennes, France
    Int J Cancer 123:395-400. 2008
    ....

Research Grants1

  1. Genetic and molecular characterization of kidney cancer
    Allan Pantuck; Fiscal Year: 2005
    ..abstract_text> ..